Petefészekrák: vizsgálatok itt: Görögország
11 trials · From ClinicalTrials.gov, checked 2026. november 13.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Athens, Chaïdári
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Athens, Thessaloniki
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Athens, Pátrai, Rio, Thessaloniki
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Athens, Kalamata, Nea Kifissia
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Athens, Chaïdári, Filothei, Maroussi, Patras
- Életkor
- 18 év and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Athens, Chaïdári, Pireas, Thessaloniki
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Athens, Filothei, Maroussi, Thessaloniki
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - No phaseTaking peopleFolate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
- Where
- Athens
- Életkor
- 18 év and over
- People
- 200
- Run by
- Hellenic Cooperative Oncology Group
See details and how to joinNCT07889843 - No phaseTaking peopleInnovative Ovarian Cancer Biomarker Assays
- Where
- Athens
- Életkor
- 35 év and over
- People
- 2080 worldwide
- Run by
- National and Kapodistrian University of Athens
See details and how to joinNCT07693894 - No phaseTaking peopleCanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
- Where
- Athens
- Életkor
- 18 év to 75 év
- People
- 2130 worldwide
- Run by
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
See details and how to joinNCT07809659 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Athens, Chaïdári, Kalamata, Kifissia, Marousi, Patras, Thessaloniki
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00